Zydus Lifesciences hits a 52-week high after getting US FDA's go-ahead for Phase II trial of ZTIL1

Zydus Lifesciences Share Price: Zydus Lifesciences hit a 52-week high of Rs 672.50 on BSE on Monday (December 18, 2023) after the comnpany got approval from the US FDA to initiate Phase II clinical trial for its ZTIL1. 

The Zydus stock was trading up by 4.61 per cent, or Rs 29.80, at Rs 676.00 at 10:09 am on Monday. 

ZYIL1 tablets' annual market in the USA is estimated to be Rs 2,067.7 crore. The ZYIL1 drug will be used in Parkinson's disease.

"Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) a leading discovery-based, global pharmaceutical company, announced today that it has received permission from USFDA, to initiate the Phase II clinical study of NLRP3 inhibitor “ZYIL1” in patients with Parkinson’s disease," Zydus said in a statement on Saturday. 

ZYIL1 is a novel oral small molecule NLRP3 inhibitor. Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation, Zydus further said.

Lacosamide is used to treat partial seizures. 

So far this month, approval has been to Zydus' 6 medicines.

In the last quarter, the company got approval for 9 new products.

Nifty Pharma Index 

The Nifty Pharma index was higher by 1.44 per cent, or 233.65, at 16413.45 at 11:31 am on Monday.

The index's rise in the one month has been 3.84 per cent.

It has soared by 23.74 per cent in the six months and 30.77 per cent year to date.

The benchmark Nifty 50 index, meanwhile, has jumped by 9.03 per cent in the one month; 14.49 per cent in the six months, and 18.00 per cent year to date.